Table 1 Demographic and clinical features of patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM)

Patients

53

17

36

Age, yrs, mean ± SD

47.7 ± 11.5

47.5 ± 11.6

47.9 ± 11.6

ns

Females, n (%)

41 (77.3)

12 (70.5)

29 (80.5)

ns

BMI, mean ± SD

24.0 ± 3.6

23.6 ± 2.4

24.2 ± 4.1

ns

Age at CM onset, mean ± SD

-

34.0 ± 13.1

-

Disease duration, yrs, mean ± SD

29.6 ± 13.9

29.1 ± 13.0

29.8 ± 14.4

ns

MMDs/MHDs at baseline, mean ± SD

17.0 ± 6.2

10.5 ± 1.8

20.0 ± 5.2

-

NRS score, mean ± SD

8.6 ± 1.1

8.5 ± 1.2

8.6 ± 1.1

ns

Pain location, n (%)

 Unilateral

21 (44.7)

8 (50)

13 (41.9)

ns

 Unilateral, bilateral

23 (48.9)

8 (50)

15 (48.4)

 Bilateral

3 (6.4)

0

3 (9.7)

Pain quality, n (%)

 Pulsating

28 (57.1)

8 (53.3)

20 (58.8)

ns

 Pressing/tightening

12 (24.5)

3 (20.0)

9 (26.5)

 Other

9 (18.4)

4 (26.7)

5 (14.7)

Unilateral cranial autonomic symptoms, n (%)

33 (62.2)

12 (70.5)

21 (58.3)

ns

Allodynia, n (%)

29 (59.2)

10 (66.7)

19 (55.8)

ns

Dopaminergic symptoms, n (%)

30 (61.2)

10 (66.7)

20 (58.8)

ns

Monthly analgesic intake, mean ± SD

19.0 ± 16.5

11.9 ± 7.1

22.4 ± 18.5

0.029

MO, n (%)

-

31 (86.1)

-

Duration of MO, yrs, mean ± SD

-

24.8 ± 35.0

-

Triptan responders, n (%)

34 (64.1)

12 (70.6)

22 (61.1)

ns

Pts using concomitant prophylaxis, n (%)

29 (54.7)

7 (41.1)

22 (61.1)

ns

 Tricyclics

10 (34.5)

2 (28.5)

8 (36.4)

 Anticonvulsants

7 (24.1)

2 (28.5)

5 (22.7)

 Calcium-antagonists

1 (3.4)

0

1 (4.5)

 Serotoninergic antagonists

5 (17.2)

0

5 (22.7)

 Beta-blockers

9 (31.0)

2 (28.5)

7 (31.8)

 BoNT/A

2 (6.9)

0

2 (9.1)

 Other

6 (20.7)

2 (28.5)

4 (18.2)

Prior treatment failures, mean ± SD

4.5 ± 2.3

3.9 ± 1.5

4.7 ± 2.5

ns

 1–2

4 (8.0)

3 (17.7)

1 (3.0)

 3–4

30 (60.0)

10 (58.8)

20 (60.6)

  > 4

16 (32.0)

4 (23.5)

12 (36.4)

BoNT/A responders^a, n (%)

2 (11.1)

2 (33.3)

0

0.098

Pts with ≥ 1 comorbidity, n (%)

34 (64.2)

14 (82.4)

20 (55.5)

0.072

Pts with psychiatric comorbidities, n (%)

10 (19.2)

3 (18.8)

7 (19.4)

ns

HIT-6 score, mean ± SD

65.2 ± 17.2

68.2 ± 3.4

63.7 ± 20.8

ns

MIDAS score, mean ± SD

89.4 ± 48.9

78.9 ± 50.5

94.5 ± 48.1

ns

Fremanezumab dosing regimen, n (%)

 Monthly

44 (83.0)

13 (76.5)

31 (86.1)

ns

 Quarterly

9 (17.0)

4 (23.5)

5 (13.9)